Voyager Provides Update on SOD1 ALS Gene Therapy Program
Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into mid-2027 – - All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON,
Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...
Roy and his wife, Jamie, asked Wake County to offer that lump sum to officers like him who medically retire but don’t ...
Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...
Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...
The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032. Sporadic ALS Holds The Largest Market Share In The Type ...
ZEPHYRHILLS — Former Zephyrhills High football coach Tom Fisher, who spent the better part of two decades carving highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback